Debunking the IP and Access to Medicines Myth Once and For All

Posted by:

Pugatch Consilium is today releasing the report Unlocking Global Health Strengthening Availability of Essential Medicines by Enhancing Healthcare Financing and Reducing Supply Chain Costs.

This report examines a common misperception in the international community: that patents and IP incentives block access to medicines.

 

An age-old debate: Patents and access

Discussions over the impact – positive or negative; rarely neutral – that IP rights have had and continue to have on the creation and dissemination of new ideas and commercial products is ...

Continue Reading →
0

To SPC or not to SPC…

Posted by:

Does the EU Commission really think weakening IP incentives for biopharmaceutical innovation in Europe is going to create more jobs and economic activity?

by Dr David Torstensson, Partner, Pugatch Consilium

As an industry the research-based biopharmaceutical sector is one of Europe’s biggest success stories. Companies like Novartis, Roche, Sanofi Aventis, Novo Nordisk, AstraZeneca and GSK are some of the largest, most innovative and successful research-based biopharmaceutical companies in the world. Not only do these companies have a long track record of producing ...

Continue Reading →
0

BCI 2017 Report and Results Released

Posted by:

Pugatch Consilium has released the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Survey. An executive opinion survey, in 2017 the BCI polled business leaders and local general managers from the biopharmaceutical industry about the investment environment in 31 markets. The results are available in the linked report below.

 

The headline results of the 2017 BCI Survey include:

 

  • The policy environment matters a great deal for biopharmaceutical investment decisions. Economies with policies supporting biopharmaceutical innovation and investment are much more likely to actually secure ...
Continue Reading →
0

Unintended Consequences

Posted by:

Pugatch Consilium releases new study on the negative economic consequences of an SPC export exemption in Europe

Today Pugatch Consilium releases UNINTENDED CONSEQUENCES: How introducing a manufacturing and export exemption to supplementary protection certificates would weaken global standards of IP protection and result in direct losses to Europe’s research-based biopharmaceutical industry.

The study (which is also available via the Social Science Research Network, SSRN) models the economic impact an SPC manufacturing and export exemption would have on the European and global research-based ...

Continue Reading →
0

Preliminary BCI 2017 Results and New Impact Analysis Published

Posted by:

In a world of global investment flows, securing a larger portion of the $150 billion invested per year by the research-based biopharmaceutical industry is anyone’s game. The 2017 results of the annual Biopharmaceutical Competitiveness & Investment (BCI) Survey, previewed at the International BIO Convention in San Diego in June, reveal that biopharmaceutical competitiveness turns on the policy conditions that countries decide to put in place.

 

A new blog post by Prof Meir Pugatch on PhRMA’s The Catalyst discusses these results and ...

Continue Reading →
0

BIO 2017

Posted by:

Professor Meir Pugatch and Dr. David Torstensson are speaking today at the BIO international convention held in San Diego, CA. Sponsored by the Biotechnology Innovation Organization, the annual convention hosts more than 16,000 attendees from over 70 countries.

 

Yesterday Professor Pugatch participated in a high level discussion within the What in the World Matters? The Challenge of Spurring Innovation in Global Markets panel, which focused on the relatively slow uptake of biotech innovation in economies outside the US, and ...

Continue Reading →
0

Building a Bioeconomy: A how-to guide

Posted by:

New study shows how countries can succeed in developing and building their biotech capabilities

A new study by international research consultancy Pugatch Consilium (commissioned by the Biotechnology Industry Organization) examines those national innovation strategies, policies and best practices that have been successful in creating an environment in which biotechnologies and biotechnological innovation can flourish.

2017 marks the fourth edition of the Building the Bioeconomy series of papers examining national biotechnology industrial policies. This year’s edition includes 26 countries from all major regions ...

Continue Reading →
0

III Semana de Innovación en Salud (Week of Innovation in Health) Event

Posted by:

Ma’ayan Laufer, a Senior Consultant at Pugatch Consilium, spoke last week at the III Semana de Innovación en Salud (Week of Innovation in Health) event, held at Mexico City. Ma’ayan’s presentation focused on Mexico’s performance vis-à-vis global leaders in biomedical innovation as reflected in Pugatch Consilium’s international indices – including the Building the Bioeconomy series, the International IP Index and the Biopharmaceutical Competitiveness and Investment (BCI) Index.

Continue Reading →

0

Professor Meir Pugatch and U.S. Chamber of Commerce President Tom Donohue launch new fifth edition of the U.S. Chamber of Commerce’s International IP Index

Posted by:

Professor Meir Pugatch spoke together with Tom Donohue (President and CEO of the U.S. Chamber of Commerce), David Hirschmann (President and CEO of the U.S. Chamber of Commerce Global Intellectual Property Center) and former Director of the United States Patent and Trademark Office, David Kappos, at the launch of the fifth edition of the U.S. Chamber’s International IP Index in Washington D.C earlier this week.

Continue Reading →

0

Pugatch Consilium Releases New Study on Regulatory Standards for Approval of Generic Medicines

Posted by:

Today Pugatch Consilium releases Generic drugs appraisal and approval: departing from the ‘one-size-fits-all’ approach.

Generic medicines – follow-on versions of off-patent innovative medicines – are designed to be interchangeable to the innovative reference product. As more sophisticated and complex medicines are developed, securing the safe and effective use of their follow-on products becomes increasingly challenging.

This report zeroes in on the existing gaps and challenges within the ‘one-size-fits-all’ model of generic drugs approval vis-à-vis two particularly complex drugs: Narrow Therapeutic Index (NTI ...

Continue Reading →
0
Page 1 of 13 12345...»